BridgeBio Pharma annual operating income
2017
2018
2019
2020
2021
2022
2023
2024
2025
BridgeBio Pharma Operating Income Growth & History (BBIO)
BridgeBio Pharma's operating income was −$523.4M for fiscal 2025.
View full BridgeBio Pharma company overviewBridgeBio Pharma annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$523.4M | $69.6M | — |
| 2024 | 2024-12-31 | −$593.0M | $14.4M | — |
| 2023 | 2023-12-31 | −$607.4M | −$95.2M | — |
| 2022 | 2022-12-31 | −$512.2M | $64.4M | — |
| 2021 | 2021-12-31 | −$576.6M | −$102.2M | — |
| 2020 | 2020-12-31 | −$474.5M | −$208.2M | — |
| 2019 | 2019-12-31 | −$266.2M | −$82.6M | — |
| 2018 | 2018-12-31 | −$183.7M | −$139.8M | — |
| 2017 | 2017-12-31 | −$43.9M | — | — |
BridgeBio Pharma quarterly operating income
Q3.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$107.1M | $27.2M | — |
| Q1 2026 | 2026-03-31 | −$106.0M | −$1.6M | — |
| Q4 2025 | 2025-12-31 | −$139.6M | $86.5M | — |
| Q3 2025 | 2025-09-30 | −$145.2M | $46.6M | — |
| Q2 2025 | 2025-06-30 | −$134.3M | $41.3M | — |
| Q1 2025 | 2025-03-31 | −$104.4M | −$104.7M | — |
| Q4 2024 | 2024-12-31 | −$226.0M | −$48.6M | — |
| Q3 2024 | 2024-09-30 | −$191.8M | −$34.1M | — |
| Q2 2024 | 2024-06-30 | −$175.5M | −$29.4M | — |
| Q1 2024 | 2024-03-31 | $343,000 | $126.5M | — |
| Q4 2023 | 2023-12-31 | −$177.4M | −$48.2M | — |
| Q3 2023 | 2023-09-30 | −$157.7M | −$28.6M | — |
| Q2 2023 | 2023-06-30 | −$146.1M | −$65.9M | — |
| Q1 2023 | 2023-03-31 | −$126.2M | $47.5M | — |
| Q4 2022 | 2022-12-31 | −$129.2M | $36.4M | — |
| Q3 2022 | 2022-09-30 | −$129.1M | $20.4M | — |
| Q2 2022 | 2022-06-30 | −$80.2M | $13.8M | — |
| Q1 2022 | 2022-03-31 | −$173.7M | −$6.2M | — |
| Q4 2021 | 2021-12-31 | −$165.6M | −$38.1M | — |
| Q3 2021 | 2021-09-30 | −$149.5M | −$29.6M | — |
| Q2 2021 | 2021-06-30 | −$94.0M | $30.6M | — |
| Q1 2021 | 2021-03-31 | −$167.5M | −$65.0M | — |
| Q4 2020 | 2020-12-31 | −$127.5M | −$48.9M | — |
| Q3 2020 | 2020-09-30 | −$119.9M | −$65.4M | — |
| Q2 2020 | 2020-06-30 | −$124.6M | −$55.2M | — |
| Q1 2020 | 2020-03-31 | −$102.5M | −$38.7M | — |
| Q4 2019 | 2019-12-31 | −$78.6M | — | — |
| Q3 2019 | 2019-09-30 | −$54.5M | −$13.1M | — |
| Q2 2019 | 2019-06-30 | −$69.3M | — | — |
| Q1 2019 | 2019-03-31 | −$63.8M | — | — |
| Q3 2018 | 2018-09-30 | −$41.5M | — | — |
BridgeBio Pharma operating income trends
Over the last five fiscal years, BridgeBio Pharma's operating income decreased from −$474.5M to −$523.4M, a change of −$48.9M. The latest reported quarter, Q2 2026, shows −$107.1M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BridgeBio Pharma source filings ↗Community posts
BridgeBio’s Attruby sales expand as a one-time milestone boosts quarterly revenue
BridgeBio ($BBIO) reported third-quarter 2026 revenue of $353.2 million, compared with $120.7 million a year earlier. US Attruby sales reached $253.2 million, increasing approximately $31 million sequentially and $145 million year over year ...
